PLASMA CELL MYELOMA

This study is testing whether a new COVID-19 vaccine called GEO-CM04S1 can trigger a stronger immune response than the standard mRNA vaccines in a particularly vulnerable group. It involves 63 adults with blood cancers (like leukemia or lymphoma) who have received a stem cell tra…

This early-stage trial is testing whether adding specially treated immune cells, called 'veto cells,' can help patients with blood cancers or bone marrow failure after a stem cell transplant. The goal is to help the donor's cells grow in the patient's body without causing a dange…

This large study aims to find the best long-term treatment plan for people newly diagnosed with a specific type of multiple myeloma, a cancer of plasma cells. It compares two different three-drug combinations to see which is more effective at controlling the disease. After the in…

This study is testing a new combination of four drugs for people newly diagnosed with multiple myeloma, a cancer of plasma cells. The goal is to find the safest and most effective dose and see how well the drugs work together to control the cancer. Researchers will closely monito…

This study is testing whether people with multiple myeloma who are in a deep, sustained remission can safely stop their maintenance therapy. Researchers want to see if active monitoring without ongoing treatment can keep the cancer in remission for at least one year. The goal is …

This study is testing if giving the drug daratumumab after a patient's own stem cell transplant helps control multiple myeloma for a longer time. It involves 31 patients who have had the transplant. The main goal is to see if this extra treatment can prevent the cancer from progr…

This study tests whether adding a targeted drug called belantamab mafodotin to standard lenalidomide treatment can eliminate tiny amounts of remaining cancer cells in multiple myeloma patients who have had a stem cell transplant. The goal is to help patients achieve and maintain …

This study is testing whether adding the immunotherapy drug elotuzumab to standard maintenance therapy (lenalidomide) helps keep multiple myeloma from returning after a patient's own stem cell transplant. The trial involves 113 patients who have recently undergone transplant for …

This early-stage study is testing whether immune cells from healthy donors, given along with two other drugs, are safe for people with advanced colorectal, stomach, or hard-to-treat blood cancers. The goal is to see if this combination helps the donor immune cells last longer in …

This study is testing whether adding a new drug called isatuximab to a standard two-drug combination can delay or prevent high-risk smoldering multiple myeloma from progressing to active, symptomatic disease. It will involve about 337 patients who have the high-risk early form of…

This study is testing a special website designed to help young women recently diagnosed with cancer make decisions about preserving their fertility. The goal is to see if the website reduces the stress and uncertainty of these choices by providing clear information. Researchers a…

This study aims to understand why cancer survivors who receive stem cell transplants have a higher risk of heart disease. Researchers will measure how well the heart, lungs, and muscles work together in 350 adult patients before their transplant and for two years after. The goal …